NEW YORK (GenomeWeb News) – PrognosDx Health today announced a deal with Accium BioScience to develop and commercialize tests based on histone biomarkers.
Palo Alto, Calif.-based PrognosDx will lend its expertise and epigenetic platform technology to the partnership, while Accium, headquartered in Seattle, will contribute its accelerator mass spectrometry platform.
PrognosDx's epigenetic technology is based on the predictive power of global histone modification patterns and is licensed from the University of California, Los Angeles.
Accelerator mass spectrometry is used in Phase I clinical studies of new chemical entities. In addition to use of the technology to develop new drugs in partnerships with pharmaceutical firms, Accium is developing use of accelerator mass spectrometry "in a range of diagnostic tests with potential utility in personalized medicine," including a project to identify pharmacologic and pharmacodynamic endpoints that may be predictive of individual patient response to Merck's Temodar (temozolomide).
Terms of today's deal were not disclosed.
PrognosDx also announced that Jeffrey Wolf has joined the company's scientific advisory board. Wolf is director of the Multiple Myeloma Program in the division of hematology and oncology at the Helen Diller Family Comprehensive Cancer Center. He is also a clinical professor of medicine at the University of California, San Francisco.